Henan Taloph Pharmaceutical Stock Co Ltd
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, pediatric Qingrezhike oral liquid, Huoxiangzhengqi mixture, Danshen and Wuzi Yanzong oral liquid, Shengmaiyin, pediatric compound chicken gizzard chew… Read more
Henan Taloph Pharmaceutical Stock Co Ltd (600222) - Total Assets
Latest total assets as of September 2025: CN¥3.74 Billion CNY
Based on the latest financial reports, Henan Taloph Pharmaceutical Stock Co Ltd (600222) holds total assets worth CN¥3.74 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Henan Taloph Pharmaceutical Stock Co Ltd - Total Assets Trend (1996–2024)
This chart illustrates how Henan Taloph Pharmaceutical Stock Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Henan Taloph Pharmaceutical Stock Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Henan Taloph Pharmaceutical Stock Co Ltd's total assets of CN¥3.74 Billion consist of 54.6% current assets and 45.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.2% |
| Accounts Receivable | CN¥1.17 Billion | 33.5% |
| Inventory | CN¥367.67 Million | 10.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥78.99 Million | 2.3% |
| Goodwill | CN¥286.49 Million | 8.2% |
Asset Composition Trend (1996–2024)
This chart illustrates how Henan Taloph Pharmaceutical Stock Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Henan Taloph Pharmaceutical Stock Co Ltd's current assets represent 54.6% of total assets in 2024, a decrease from 72.0% in 1996.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2024, up from 1.1% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 3.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 33.5% of total assets.
Henan Taloph Pharmaceutical Stock Co Ltd Competitors by Total Assets
Key competitors of Henan Taloph Pharmaceutical Stock Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Henan Taloph Pharmaceutical Stock Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Henan Taloph Pharmaceutical Stock Co Ltd generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Henan Taloph Pharmaceutical Stock Co Ltd generates $ 1.45 in net profit.
Henan Taloph Pharmaceutical Stock Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 1.07 | 1.25 |
| Quick Ratio | 0.90 | 0.81 | 1.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥295.65 Million | CN¥ 148.33 Million | CN¥ 378.49 Million |
Henan Taloph Pharmaceutical Stock Co Ltd - Advanced Valuation Insights
This section examines the relationship between Henan Taloph Pharmaceutical Stock Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -2.4% |
| Total Assets | CN¥3.49 Billion |
| Market Capitalization | $411.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Henan Taloph Pharmaceutical Stock Co Ltd's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Henan Taloph Pharmaceutical Stock Co Ltd's assets decreased by 2.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Henan Taloph Pharmaceutical Stock Co Ltd (1996–2024)
The table below shows the annual total assets of Henan Taloph Pharmaceutical Stock Co Ltd from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.49 Billion | -2.43% |
| 2023-12-31 | CN¥3.58 Billion | -0.65% |
| 2022-12-31 | CN¥3.60 Billion | -4.85% |
| 2021-12-31 | CN¥3.78 Billion | +11.64% |
| 2020-12-31 | CN¥3.39 Billion | +23.73% |
| 2019-12-31 | CN¥2.74 Billion | -3.38% |
| 2018-12-31 | CN¥2.84 Billion | +0.97% |
| 2017-12-31 | CN¥2.81 Billion | +5.94% |
| 2016-12-31 | CN¥2.65 Billion | +0.43% |
| 2015-12-31 | CN¥2.64 Billion | +15.18% |
| 2014-12-31 | CN¥2.29 Billion | +17.31% |
| 2013-12-31 | CN¥1.95 Billion | +24.48% |
| 2012-12-31 | CN¥1.57 Billion | +7.48% |
| 2011-12-31 | CN¥1.46 Billion | +16.70% |
| 2010-12-31 | CN¥1.25 Billion | +14.57% |
| 2009-12-31 | CN¥1.09 Billion | +16.63% |
| 2008-12-31 | CN¥936.40 Million | +10.83% |
| 2007-12-31 | CN¥844.86 Million | +4.40% |
| 2006-12-31 | CN¥809.29 Million | +7.81% |
| 2005-12-31 | CN¥750.66 Million | +1.56% |
| 2004-12-31 | CN¥739.11 Million | +4.25% |
| 2003-12-31 | CN¥708.97 Million | +2.30% |
| 2002-12-31 | CN¥693.00 Million | +11.25% |
| 2001-12-31 | CN¥622.91 Million | +8.74% |
| 2000-12-31 | CN¥572.86 Million | +3.65% |
| 1999-12-31 | CN¥552.67 Million | +72.91% |
| 1998-12-31 | CN¥319.63 Million | +23.34% |
| 1997-12-31 | CN¥259.15 Million | +15.01% |
| 1996-12-31 | CN¥225.34 Million | -- |